Articles tagged with Prostate Cancer
A study suggests that delayed surgical intervention can be a safe alternative to immediate treatment for men diagnosed with early-stage, low-grade prostate cancer. The research found equivalent risks of noncurable prostate cancer in both groups, depending on factors like age and PSA levels.
A new study found that androgen deprivation therapy is ineffective in preventing the spread of localized prostate cancer, despite its increasing use among men with non-spreading disease. Researchers suggest that men may endure significant side effects for uncertain benefits.
Researchers found that a common osteoporosis treatment helped men with prostate cancer recover significant bone mass after two years of androgen deprivation therapy. The study suggests that bone density tests should be encouraged for men at risk, and bone-preserving therapy could prevent debilitating fractures.
A large population-based study found that older men with early prostate cancer who received radiation therapy or surgery lived significantly longer than those who were observed. The study, which examined over 48,000 men between 65 and 80 years old, demonstrated a survival advantage for treatment over observation.
Researchers found that administration of a bisphosphonate called zoledronic acid every three months significantly increased bone density in men with advanced prostate cancer. The study supports guidelines for monitoring bone density and initiating treatment to prevent fractures.
Research suggests that antioxidant supplementation with vitamin E, vitamin C, and beta-carotene is not associated with a decreased risk of prostate cancer. However, specific subgroups, such as current or recent smokers, may benefit from high-dose vitamin E supplementation to reduce advanced prostate cancer risk.
A study of 61,228 men aged 65 and older with local or regional stage prostate cancer found that lower socioeconomic status was significantly associated with decreased survival. Socioeconomic factors, including education level and community poverty, were the primary drivers of disparities in survival.
A new study from UCSD found that macrophage signaling can activate processes in both cancer cells and immune cells, altering the activity of androgen antagonists and allowing tumor growth. The research identifies a novel binding site on steroid receptors that makes them responsive to inflammatory signals.
Macrophage interaction reverses activity of hormone receptors in prostate cancer cells, leading to shifts in gene expression and drug resistance.
Researchers discovered that vitamin D significantly limits the ability of prostate cancer cells to invade healthy cells by reducing two key enzymes. Vitamin D also increases counterpart enzymes that inhibit these proteases, leading to reduced cancer progression.
A study found that only 25% of high-risk black men aged 60-69 are screened for prostate cancer, compared to 81% of white men. This disparity highlights a need for increased awareness and targeted screening efforts among black males with positive family histories.
Researchers found that specific single-nucleotide polymorphisms (SNPs) in the IGF1 gene were linked to an increased risk of prostate cancer, accounting for 10% of cases. The study's findings suggest a biologic effect across different ethnic groups.
Researchers found that the combination of curcumin and PEITC significantly retards prostate cancer tumor growth in laboratory mice. The discovery suggests potential for using plant-based compounds as alternative therapies to treat advanced prostate cancers.
A study published in the Journal of the American Medical Association (JAMA) found that screening for prostate cancer does not necessarily prolong survival. The research, which included over 72,000 veterans, showed that even men who received screenings were not at lower risk of death from prostate cancer.
A study of over 1,000 male veterans found that prostate cancer screening with PSA testing did not prolong survival. Researchers compared men who died from prostate cancer to those living with the disease and found no difference in screening rates.
Researchers at the Burnham Institute, along with partners from six institutions, are working on a NCI-funded project to develop an accurate early-stage diagnosis method for prostate cancer. The goal is to identify specific gene products indicative of the disease's clinical behavior.
Researchers will use a tumor biopsy or blood examination to identify a 'gene signature' that indicates aggressive prostate cancer, allowing patients to make informed treatment decisions. The study aims to improve outcomes for up to 30% of men with prostate cancer who do not require radical treatments.
Researchers found significant associations between PSA velocity and demographic characteristics like age, race, and diet. Men who gained or lost weight had distinct changes in PSA velocity, while African Americans had higher velocities on average.
Researchers have developed a new cell line to study prostate cancer and its effects on the body. Anti-nerve growth factor therapy shows promise in reducing skeletal pain associated with prostate cancer, outperforming morphine.
A study found that Ack1 is a key driver of tumor growth in prostate cancer, and its inhibition can slow tumor formation. The researchers also discovered an experimental drug called geldanamycin that can inhibit Ack1 activity by interfering with its molecular interactions.
A study of 24 patients found that MRI with an endorectal coil at 1.5T outperforms conventional body coils in staging prostate cancer. The results suggest a need for advances in coil technology to improve imaging at higher field strengths.
The study found that patients with rapid increases in PSA levels (PSAV) or quick doubling of PSA levels (PSADT) were more likely to experience cancer spread, recurrence, and death. These findings provide valuable pretreatment prognostic factors for prostate cancer.
A recent Columbia University study published in Nutrition and Cancer showed that Zyflamend reduces prostate cancer cell proliferation by up to 78% and induces cancer cell death. The research confirms Zyflamend's COX-1 and COX-2 anti-inflammatory effects, with independent anti-cancer benefits against prostate cancer cells.
A new study found that a vitamin D pill combination extended the lives of men with advanced prostate cancer by about eight months compared to those receiving chemotherapy and placebo. The pill, DN-101, also protected against major side effects of chemotherapy.
A Dutch study found that higher doses of radiotherapy significantly improved patient outcome over a five-year period. An anti-androgen therapy trial suggested early treatment can benefit locally advanced disease, while immunotherapy trials are showing promising results for androgen-independent prostate cancer.
Researchers developed nanoparticles that can target and deliver drugs to prostate cancer cells using aptamers, achieving highly specific and efficient tumour targeting. The bioconjugates successfully adhered to PSMA-positive prostate cancer cells and were rapidly internalised into the targeted cells.
Researchers discovered that calcitriol and QW-1624-F2-2 slowed prostate cancer progression in intact mice after 14 weeks of treatment, reducing tumor burden. However, chronic treatment showed side effects, highlighting the need for further studies to understand how these agents prevent prostate cancer.
A protein called TAP has been found to suppress prostate cancer growth and enhance the effects of vitamin E. High levels of TAP in normal prostate cells suggest it facilitates the transport of vitamin E into tissue and helps retain high concentrations.
A novel computational model predicts androgen receptor binding sites in the prostate cancer genome. Experimental verification confirms the accuracy of the model, providing new insights into prostate cancer biology.
Researchers found a unique molecular signature of fused genes in most prostate cancer tissue samples but not in benign tissue. The discovery could lead to a diagnostic test that detects the fused genes or their protein products, making it more accurate than current screening tests.
Researchers analyzed human genome variation in various populations to understand disease susceptibility, reproductive success and genetic disorders. Gene conversion played a critical role in shaping the genetic diversity of the Luteinizing Hormone/Chorionic Gonadotropin Beta cluster, which is associated with pregnancy success.
A study by Case Western Reserve University researchers found that apigenin, a plant flavonoid, slowed tumor growth in mice with prostate cancer. Apigenin also reduced IGF-1 levels associated with increased cancer risk and triggered cell self-destruction.
A study of 1,492 men found that annual PSA testing reduced the risk of dying from prostate cancer by 3.6%, while increasing the chances of diagnosis with curable cancers. The test measures levels of prostate-specific antigen, a protein produced by the prostate.
Researchers have identified a strong biomarker, MDM2, that predicts more aggressive forms of prostate cancer. This overexpression is associated with an increased chance of metastasis and death from the disease.
A study conducted between 1988 and 1995 found that radiation therapy significantly improved five- and 10-year prostate cancer-free survival rates. The treatment reduced the risk of recurrence, cancer spread, and overall mortality in patients with advanced stage prostate cancer.
Researchers at UCLA have identified how an antibody blocks prostate cancer growth by signaling cells to stop growing and die. The discovery could lead to a new treatment targeting prostate stem cell antigen, also found in bladder and pancreatic cancers.
A study by Fox Chase Cancer Center found no significant impact of type II diabetes on the initial profile or treatment outcomes of prostate cancer. However, men with type II diabetes experienced significantly worse long-term overall survival rates compared to those without diabetes.
A Fox Chase study found that men with a history of TURP (transurethral resection of the prostate) and an intermediate PSA level are at higher risk for prostate cancer recurrence. This misleads doctors about disease extent, potentially leading to less aggressive treatment.
A new study found that short-term hormone therapy can significantly improve the outlook for men with early-stage prostate cancer. Researchers discovered that testosterone suppression before and during radiotherapy reduced the risk of relapse by up to 44%.
A recent study has found that patients who are obese at age 40 and experience rapid weight gain have a higher risk of prostate cancer recurrence. The research, published by the American Association for Cancer Research, suggests that men who gained an average of three and a half pounds per year are more likely to experience biochemical ...
A study of 526 prostate cancer patients suggests that a man's body mass at different ages and adult weight gain can predict the risk of progression after surgery. Researchers found that obese men and those who gained weight quickly experienced biochemical failure more often.
Researchers found that pomegranate extract killed more cells at higher doses, and mice treated with pomegranate extract showed slowing of cancer progression and reduced PSA levels. The study adds to growing evidence that pomegranates have powerful agents against cancer.
Researchers at U-M have developed a new blood test for prostate cancer that uses 22 biomarkers to accurately identify cancerous samples. The test shows promise as a supplement or replacement for current PSA testing methods, which can produce false positives and unnecessary biopsies.
Mutations in the EphB2 gene are found in 15% of African-American men with a strong family history, compared to 5% without a history. This gene mutation is associated with an increased risk of prostate cancer in African-American men, particularly those with a family history.
Researchers found that a tumor suppressor gene Nkx3.1 plays a crucial role in protecting cells from oxygen damage, which can lead to prostate cancer. Antioxidants may be useful for prostate cancer prevention by regulating oxidative stress pathways.
A randomized trial found that high-dose radiation therapy reduced the risk of prostate cancer recurrence by 49% compared to conventional-dose therapy. The study showed improved biochemical control and local tumor control without significant differences in overall survival rates or adverse effects.
Men with high PSA levels prior to prostate removal surgery were significantly more likely to have advanced clinical stages of cancer and higher grade cancers in surgically removed tissue. Increasing PSA levels after surgery were also associated with increased risk of cancer recurrence.
A study found that nearly 60% of prostate cancer specimens received higher Gleason scores than original assignments, suggesting that pathologists are more likely to assign high scores to contemporary tumor samples. This 'Will Rogers phenomenon' may lead to a false sense of therapeutic accomplishment and skew mortality rates.
Prostate cancer cells manipulate Wnt signaling proteins to establish themselves in bone tissue, producing dense bony lesions characteristic of prostate cancer. The study found that altered levels of Wnt activity promote osteoblastic lesions, while high levels of DKK-1 inhibit Wnt activity, leading to highly osteolytic tumor lesions.
Activated vitamin D, when combined with NSAIDs, may offer a more tolerable treatment option for prostate cancer. The drug combination limits prostate cancer cell growth by targeting the same molecules attacked by NSAIDs, promoting the breakdown of prostaglandin hormones.
A Stanford study found that combining vitamin D and nonsteroidal anti-inflammatory drugs (NSAIDs) suppresses prostate cancer growth more effectively than using either drug alone. The researchers discovered a 25-70% reduction in cell growth when calcitriol was used with NSAIDs, with potential implications for new treatment options.
The National Foundation for Cancer Research (NFCR) and the Prostate Cancer Foundation have partnered with the Burnham Institute to develop a 3D culture system that simulates tumor microenvironments. This technology enables rapid testing of candidate drugs and has potential applications beyond cancer research.
Researchers found that activated Stat5 levels in prostate cancer cells predict disease progression and survival rates. Patients with high levels of activated Stat5 had a 15-year progression-free survival rate of 46% compared to 62% without activated Stat5.
A randomized, controlled trial found that comprehensive lifestyle changes, including a vegan diet and moderate exercise, can decrease PSA levels and inhibit prostate tumor growth in men with prostate cancer. The study suggests that making lifestyle changes may help prevent or reverse prostate cancer progression.
Researchers found that immediate postoperative radiotherapy significantly improved biochemical progression-free survival for patients at risk of relapse, with a 74% success rate compared to 53%. Long-term follow-up is needed to assess its effects on distant metastases and survival.
A new technique called the Checkerboard Tissue Microarray (TMA) Method has been developed to accurately predict prostate cancer aggressiveness. This method can help identify markers of aggressive tumors, potentially preventing thousands of men from undergoing unnecessary radical surgery and its severe side effects.
Researchers found that prostate tumor growth is arrested through cellular senescence, which stops cells from proliferating and responding to normal growth signals. Drugs that support p53 function may delay progression of prostate cancer by triggering cellular senescence.
Lowering PSA cutoff from 4.0 ng/mL to 2.5 ng/mL would call for more biopsies, with 10.7% of US men aged 50-59 and 17% of those aged 60-69 affected.
A study found that a rapid increase in PSA levels (PSA velocity) is associated with a higher risk of death from prostate cancer following radiation therapy. Men with low-risk disease and high PSA velocity had a 19% 7-year mortality rate, compared to 0% for those with low PSA velocity.
A study found that PSA doubling time, pathological Gleason score, and time from surgery to biochemical recurrence are significant risk factors for prostate-specific death. Patients at high risk can be identified and offered aggressive treatment, while those at low risk can be safely observed.